LinkedIn
WebsiteIntroduction
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) is a clinical-stage biotechnology company headquartered in Princeton, New Jersey. Founded in 2011, Sonnet develops targeted immuno-oncology drugs using its proprietary FHAB™ (Fully Human Albumin-Binding) technology. This platform utilizes a fully human single-chain antibody fragment that binds to human serum albumin to facilitate the delivery of therapeutic agents to tumor and lymphatic tissues.
Corporate Structure
Sonnet BioTherapeutics operates with a workforce of 11–50 employees. The company is led by interim Chief Executive Officer Raghu Rao and overseen by a Board of Directors chaired by Nailesh Bhatt. The management and scientific personnel possess expertise in cytokine biology, clinical development, and regulatory affairs.
Immuno-oncology by National Cancer Institute
Recent Developments and News
On July 14, 2025, Sonnet entered into a definitive Business Combination Agreement with Rorschach I LLC and related sponsors to form Hyperliquid Strategies Inc. (HSI). Upon closing, HSI is anticipated to have approximately 12.6 million HYPE tokens, valued at $583 million, along with at least $305 million in cash, leading to a total projected closing value of $888 million. Strategic investors involved include Paradigm Operations LP, Galaxy Digital, and Pantera Capital. Bob Diamond is expected to serve as Chairman of HSI, with David Schamis as CEO.
On the same date, Sonnet announced a private placement aimed at raising $5.5 million from accredited investors through the issuance of non-voting convertible preferred stock and warrants, which was intended to close on July 14, 2025.
At a special meeting of stockholders on November 19, 2025, over 95% of votes cast approved the proposed business combination. The meeting was subsequently adjourned to December 2, 2025, to allow for additional voting and resumed with the required approvals secured. Sonnet continues its collaborations with Roche regarding SON-1010 and with the Sarcoma Oncology Center on investigator-initiated trials.
Financial and Strategic Analysis
As of December 2, 2025, Sonnet’s share price closed at $1.7448, reflecting a 43.72% decline on a trading volume of 2,060,749 shares on the NASDAQ. The company’s 52-week trading range is $1.08 to $19.30.
Key financial metrics (TTM figures unless otherwise noted):
- Revenue: $1.0 million
- Net loss: $13.56 million
- Diluted EPS: –$6.82
- Total cash (most recent quarter): $0.32 million
- Market capitalization (intraday): approximately $12–25 million
- Price/Sales: 10.07
- Beta (5Y): 1.47
Sonnet currently has no reported P/E ratio due to its net losses. The company's financial sustainability and ability to fund clinical programs will, in part, depend on the completion of the HYPE-backed business combination and the proceeds from the July private placement.
Market Position and Industry Context
Sonnet operates within the competitive immuno-oncology sector, focusing on treatments for solid tumors. Its FHAB™ platform is engineered to improve the half-life and tumor targeting of cytokines. The current pipeline includes five cytokine-derived candidates:
- SON-1010 (IL-12-FHAB) in Phase 1, in combination with atezolizumab for platinum-resistant ovarian cancer
- SON-1210 (IL-12-FHAB-IL-15) entering Phase 1/2a for solid tumors
- SON-080 (rhIL-6) in Phase 1b/2a for chemotherapy-induced peripheral neuropathy
- Two additional preclinical programs
Collaborations with Roche and ongoing investigator-initiated studies are part of Sonnet’s strategy to mitigate clinical development risks. The proposed shift toward a cryptocurrency treasury model via Hyperliquid Strategies indicates a strategic diversification into digital asset management.
tl;dr
On December 2, 2025, Sonnet’s stock closed at $1.74, down 43.7% amid significant trading activity. The company is proceeding with a business combination to form Hyperliquid Strategies Inc., which is backed by $583 million in HYPE tokens and $305 million in cash, while also raising $5.5 million in July. Stockholders approved the merger at the adjourned November 19, 2025, meeting. Sonnet's clinical programs continue to focus on solid tumors under the FHAB™ platform, while the firm is also transitioning part of its balance sheet towards a cryptocurrency treasury reserve strategy.
